Pharma Videos

Levers For Streamlining And Optimizing The Biosimilar Process

The panel discussed how biosimilar developers can streamline production by leveraging modern cell‑line engineering and a systematic set of process levers. Unlike de‑novo biologics, biosimilars must replicate a defined quality attribute envelope while seeking cost efficiencies. Advances in CHO cell line development now deliver 5‑10 g/L titers, a dramatic jump from two decades ago. Developers use a two‑pronged strategy: an upstream culture that maximizes productivity without compromising critical quality attributes, and a downstream platform—protein A, ion exchange, and hydrophobic interaction chromatography—tuned to preserve those attributes. Levers such as media composition, feed strategy, pH, temperature, and dissolved‑oxygen control are explored through multivariate studies because they interact. Regulatory guidance emphasizes hitting the mid‑range of the reference product’s attribute distribution. As one speaker noted, “If you teeter on the high or low end, you risk producing lots that fall outside the acceptable range.” Analytical assays therefore become the cornerstone for defining those target windows early in development. Embedding analytics and process‑leverage optimization from the outset reduces batch‑to‑batch variability, shortens development timelines, and improves cost‑of‑goods, giving biosimilar manufacturers a competitive edge in a crowded market.